The Burden of Hepatitis Delta in Italy: Potential Impacts of Bulevirtide Through a Cost of Illness and Cost-Consequence Analyses

Speaker(s)

Cazzato D1, Marcellusi A2, Paoletti M3, Kondili L4, Coppola N5, Coco B6, Mecozzi A7, Mollea S8, Kim C9, Rock M9, Scortichini M10
1Economic Evaluation and HTA (EEHTA CEIS), Department of Economics and Finance, Faculty of Economics, University of Rome “Tor Vergata”, Roma, RM, Italy, 2University of Milan, Milan, Italy, 3Economic Evaluation and HTA (EEHTA CEIS), Department of Economics and Finance, Faculty of Economics, University of Rome “Tor Vergata”, ROMA, RM, Italy, 4Center for Global Health, Istituto Superiore di Sanità, Rome, Italy, 5Infectious Diseases Unit, Department of Mental Health and Public Medicine, University of Campania Luigi Vanvitelli, Napoli, Napoli, Italy, 6Hepatology Unit and Laboratory of Molecular Genetics and Pathology of Hepatitis Viruses, Reference Center of the Tuscany Region for Chronic Liver Disease and Cancer, Department of Medical Specialties, University Hospital of Pisa, Pisa, Toscana, Italy, 7Hospital pharmacy director, Hospital S. Eugenio-CTO, Roma, Roma, Italy, 8Gilead Sciences Srl, Milano, Milano, Italy, 9Gilead Sciences, Foster City, CA, USA, 10Economic Evaluation and HTA (EEHTA CEIS), Department of Economics and Finance, Faculty of Economics, University of Rome “Tor Vergata”, Rome, RM, Italy

Presentation Documents

OBJECTIVES: The hepatitis delta virus (HDV) is the most severe form of viral hepatitis, significantly impacting public health systems. This study aims to assess the economic impact of HDV on the National Health Service (NHS) and society in Italy and evaluate the costs and effects of introducing bulevirtide for the treatment of chronic HDV.

METHODS: A Cost of Illness (COI) analysis was conducted to estimate the economic impact of HDV. Additionally, a Cost-Consequence Analysis (CCA) was performed to evaluate the costs and effects of introducing bulevirtide compared to standard treatments (pegylated interferon alfa and best supportive care) over 10 years. The analyses involved a hypothetical cohort of 1000 adult patients with compensated cirrhosis and an average age of 45 years. Both NHS and societal perspectives were considered, including direct costs (healthcare resource utilization, monitoring, adverse events) and indirect costs (productivity loss). Outcomes included were life-years (LYs), quality-adjusted life years (QALYs) and avoided deaths, with a 3.0% discount rate applied to costs and outcomes. Finally, a deterministic sensitivity analysis was conducted to test the impact of parameters on the base case results.

RESULTS: The COI revealed an economic impact over 10 years of € 34,939,429 for managing patients with HDV in Italy. Additionally, the CCA results indicated that the introduction of bulevirtide could generate cost savings of € 2,152,753, for a total expenditure of € 32,786,677 over the same period. Moreover, the introduction of bulevirtide could lead to an increase of 6% in LYs, 8% in QALYs and a 12% reduction in the number of deaths within the considered time horizon.

CONCLUSIONS: The economic burden of HDV in Italy over 10 years for 1000 adult patients is significant. However, the results highlight the potential of bulevirtide in reducing the clinical and economic burden associated with HDV in Italy, while improving health outcomes.

Code

EE718

Topic

Economic Evaluation

Disease

No Additional Disease & Conditions/Specialized Treatment Areas